Iporuru (Alchornea castaneifolia): A Comprehensive Reference
Identity and Botanical Description
Botanical name: Alchornea castaneifolia (Humb. & Bonpl. ex Willd.) A. Juss. Family: Euphorbiaceae (formerly sometimes listed under Leguminosae in older literature). Synonyms: Hermesia castaneifolia Humb. & Bonpl. ex Willd.; Alchornea passargei Pax & K.Hoffm.
Iporuru (Alchornea castaneifolia; synonyms include Hermesia castaneifolia Humb. & Bonpl. ex Willd.) is a medicinal plant native to Amazon rainforest vegetation in Brazil. It belongs to the Euphorbiaceae family and is a medium-sized tree commonly growing alongside riverbanks, both in sandy and clay soils.
Iporuru is a shrubby tree that reaches 8–10 m in height with light-brown bark and violet flowers. It grows extensively in the lower elevations and flood plains of the Amazon River system in Peru, and is indigenous to the moist, tropical areas in Argentina, Bolivia, Brazil, Colombia, Paraguay, and Venezuela.
Iporuru can be harvested only in the Amazon's dry season; it spends the rainy season underwater. The locals believe that the active medicinal properties found in the bark are present only during the dry season.
Common Names and Vernacular Synonyms
The plant is known by multiple vernacular names: iporuru, iporoni, iporuro, ipururo, ipurosa, macochihua, niando, and pajaro. Its best-known name is the Peruvian designation iporuru, under which it circulates in international trade.
Plant Parts Used
The bark, leaves, and root are the parts used medicinally. The plant is commonly harvested from the wild for medicinal use. Iporuru remedies and products are sold in local markets and herbal pharmacies in Peru, where it is recommended highly for treating arthritis and rheumatism.
Common Dosage Forms
Iporuru is commercially available in several forms. The bark and leaves are sold as dried powder for preparation of infusions (teas), as well as in encapsulated powder form. Throughout the Amazon, the bark or leaves of iporuru are tinctured, generally with the local rum called aguardiente, as a local remedy for rheumatism, arthritis, colds, and muscle pains. The tincture form—an alcoholic maceration of the bark—is thus the most historically documented preparation, though modern supplement markets also offer the material as standardized capsules or loose leaf/bark powder.
Traditional and Historical Use
For centuries, the indigenous peoples of the Amazon have used the bark and leaves of iporuru for many different purposes and prepared it in many different ways. Iporuru has a high reputation as a medicinal herb in parts of South America, though it is little known elsewhere. The bark and leaves are used for many different purposes and are prepared in many different ways. However, it is especially valued for its anti-inflammatory and pain-relieving properties and is also widely used as an aphrodisiac and general tonic to the reproductive system.
Musculoskeletal and Rheumatic Conditions
Alcoholic bark maceration was used to treat rheumatism, arthritis, colds, and muscle pains after a long fishing day. The Candochi-Shapra and the Shipibos used the bark and roots to treat rheumatism. Iquitos herbalists recommend it for rheumatism. Pucallpa citizens take the leaf decoction orally for cough and rheumatism.
Iporuru is well known to the indigenous peoples of Peru for relieving the symptoms of osteoarthritis, and in aiding flexibility and range of motion. The pain-relieving properties of iporuru also appear in topical treatments; crushed leaves are rubbed on painful joints and are beaten into a paste to apply to painful stingray wounds.
Gastrointestinal Uses
To prevent diarrhea, members of the Tikuna tribe take one tablespoon of Alchornea castaneifolia bark decoction before meals. Throughout Peru it is regarded as a remedy for impotency as well as for balancing blood sugar levels in diabetics.
Reproductive and Aphrodisiac Uses
Iporuru has a traditional reputation for being a tonic and booster of male libido. Around Piura, the leaves are used to increase fertility of females where the male is relatively impotent. Rutter stresses that it is an aphrodisiac and geriatric for males.
Shamanic and Ritual Use
The Alchornea castaneifolia plant is commonly used with other plants during shamanistic training and sometimes is an ingredient in ayahuasca, a hallucinogenic multi-herb decoction used by South American shamans.
Broader Ethnomedical Applications
People take iporuru for painful conditions including joint and muscle pain (rheumatism), headache, and toothache. Women take it for painful or abnormal menstrual periods. Some people take iporuru to treat coughs and swollen airways (bronchitis) or to stimulate digestion and treat diarrhea. Other uses include treatment of thrush and ringworm (fungal infections), malaria, and leprosy. Men take iporuru for erectile dysfunction.
Key Chemical Constituents and Active Compounds
Little research has been done to catalog completely the phytochemicals in iporuru. Initial screening has revealed it to contain steroids, saponins, phenols, flavonols, flavones, tannins, xanthones, and alkaloids.
Alkaloids
The anti-inflammatory properties of iporuru are attributed to a group of alkaloids, including one called alchorneine, which are found in the bark of iporuru as well as several other species of Alchornea. The genus-level review of Alchornea species (MartĂnez et al., 2017) identifies a more complete alkaloid profile. Alkaloids identified in the genus include isoalchorneine, alchorneine, alchorneinone, N1,N2-diisopentenyl guanidine, N1,N2,N3-triisopentenyl guanidine, yohimbine, and pterogynidine. The presence of yohimbine in the closely related species A. cordifolia has been documented; that species presented alchornein, alchorneinone, isoalchornein, yohimbine, and other alkaloids as well as anthranilic and gentisic acids. The antiulcer study by Hiruma-Lima et al. (2006) also confirmed the presence of these alkaloids in A. castaneifolia itself: this plant presented alchornein, alchorneinone, isoalchornein, yohimbine, and other alkaloids as well as anthranilic and gentisic acids.
Phenolic Compounds and Ellagitannins
A dedicated phytochemical study published in the peer-reviewed journal Records of Natural Products (Gleńsk et al., 2014) isolated and structurally characterized the phenolic fraction of A. castaneifolia leaves using mass spectrometry and NMR. The isolated and characterized compounds were myricetin glucoside, myricetin galactoside, proanthocyanidin A1 and A2, epicatechin, gallic acid, shikimic acid, putranjivain A, elaeocarpusin, and the previously unreported methyl ester of repandusinic acid A. This study is notable for reporting the methyl ester of repandusinic acid A as a novel compound not previously isolated from any natural source.
Flavonoids
Phytochemical investigation of the hydroethanolic leaf extract and enriched flavonoidic fraction led to the isolation of flavonoid glycosides as the main compounds, suggesting that these substances may be involved in the observed antiulcer activity. Earlier work referenced in the Hiruma-Lima et al. (2006) study noted that flavonoids from A. castaneifolia were being characterized by Brazilian research groups, including the isolation of flavonoid glycosides from the leaves.
Steroids and Other Compounds
Stigmastane steroids isolated from Alchornea species include stigmasterol, stigmasta-4,22-dien-3-one, 5α-stigmastane-3,6-dione, 5α-stigmastane-23-ene-3,6-dione, 3-β-hydroxy-5α-stigmastane-24-ene, β-sitosterol, and 3-O-β-D-glucopyranosyl-β-sitosterol. Some species of the plant genus Alchornea (family Euphorbiaceae) are widely used in popular medicine, mainly in South America and Africa. Several kinds of biological activity have been seen in the species: antioxidant, antifungal, anti-inflammatory, antibacterial, cytotoxic against tumor cell lines, and inhibitory to the replication of HIV-1 and HIV-2.
Mechanisms of Action
COX Inhibition and Prostaglandin Modulation
Pharmacognosy students in Sweden documented that an ethanol extract of the stembark was capable of reducing lab-induced swelling and inflammation in rats when applied topically. These researchers also reported that the extract was able to inhibit COX-1 prostaglandin synthesis. Prostaglandins, produced by the activity of the enzyme cyclooxygenase (COX), are linked to inflammatory processes and diseases. The technical data report from Rain-Tree records the specific concentration: the stembark ethanol extract achieved COX-1 inhibition at 100 mcg/ml in a bovine seminal vesicle microsome test system.
The anti-inflammatory action appears to involve dual prostaglandin regulation: inhibiting COX-1 derived prostaglandins in the context of joint inflammation, while in the gastrointestinal context, flavonoid-rich fractions of the plant were shown to increase cytoprotective prostaglandin production. The enriched flavonoidic fraction did not modify the amount of free mucus production by gastric mucosa, but was able to increase prostaglandin production.
Modulation of Gastrointestinal Hormones
When administered to rats submitted to ethanol-induced gastric lesions, the enriched flavonoidic fraction increased the somatostatin serum levels, while the gastrin serum levels were proportionally decreased. This modulation of somatostatin upward and gastrin downward represents a plausible gastroprotective mechanism: somatostatin suppresses acid secretion and protects mucosal integrity, while elevated gastrin is associated with increased acid output and mucosal damage.
Antifungal and Antiviral Mechanisms
Preliminary in vitro research performed in Canada has reported iporuru's antifungal, antiviral, and antitumor activities. In their "crown gall tumor inhibition" assay, a preliminary laboratory test to predict antitumor activity, ethanol extracts and water extracts of the dried bark were tested. Antimicrobial testing revealed that the ethanol extract demonstrated good antifungal activity against several fungal strains, but the water extract was inactive. Likewise, ethanol extracts evidenced better antiviral actions than water-based ones. Neither the ethanol nor water extracts showed antibacterial or antiyeast actions.
Scientific Evidence by Area of Use
Anti-inflammatory and Analgesic Activity
Evidence base: preclinical (in vitro and animal); no published human clinical trials identified.
In vitro and in vivo models using bovine seminal vesicle microsomes and mice showed that the ethanolic extract exhibited moderate inhibition of COX-1 prostaglandin biosynthesis and a 55% inhibition of oedema in the ear of mice after 2 hours (Dunstan et al., 1997). This is the primary published study directly examining A. castaneifolia for anti-inflammatory activity. The study was conducted at the Department of Pharmacognosy, Faculty of Pharmacy, University of Uppsala, Sweden. Its limitations include: the topical ear-edema model is a standard screening assay but does not directly replicate the complex pathophysiology of human arthritis; the study tested the plant material as a crude ethanol extract rather than an isolated fraction; and no human data were collected.
Other researchers in the U.S. confirmed these effects by injecting mice with an ethanol extract of iporuru and observing an anti-inflammatory effect against chemical-induced inflammation. This unpublished or grey-literature observation, referenced in the Rain-Tree technical dossier, adds to the preclinical signal but cannot be independently evaluated without a full peer-reviewed publication.
The overall anti-inflammatory evidence is preliminary: supportive at the level of animal models and in vitro assays, but no randomized controlled trials (RCTs) or other human clinical investigations of A. castaneifolia for arthritis or pain have been published in indexed peer-reviewed literature as of the available data.
Antiulcer and Gastroprotective Activity
Evidence base: preclinical (animal models); no published human clinical trials identified.
The most detailed pharmacological investigation of A. castaneifolia in the peer-reviewed literature is the 2006 study by Hiruma-Lima et al., published in the Journal of Ethnopharmacology (Vol. 104, pages 215–224). The hydroethanolic extract of the leaves (HEL) and bark (HEB) from Alchornea castaneaefolia (Euphorbiaceae) were investigated for their ability to prevent ulceration of the gastric mucosa in animal models. HEL (500 and 1000 mg/kg) and HEB (1000 mg/kg) significantly reduced the gastric injuries induced by the combination of HCl/ethanol and lowered the severity of gastric damage formation induced by indomethacin/bethanechol in mice. Further investigation showed that HEL also inhibited formation of ulcers in mice submitted to stress and pylorus ligature, but HEL did not modify gastric juice parameters in Shay mice.
HEL was also effective in promoting the healing process in chronic gastric ulcer induced by acetic acid in rats. An enriched flavonoidic fraction (EFF at a dose of 100 mg/kg) obtained from HEL reduced gastric lesions induced by HCl/ethanol and indomethacin/bethanechol in mice.
The study design involved multiple well-established animal ulcer models (acid/ethanol chemical irritation, NSAID-induced, stress-induced, pylorus-ligation, and chronic acetic acid models). The results across these models were consistently protective. However, the research was entirely conducted in rodents; dose extrapolation to human use is not straightforward, and no human clinical trials have evaluated this endpoint.
Antifungal Activity
Evidence base: in vitro only.
In the "crown gall tumor inhibition" assay and antimicrobial screening, ethanol extracts and water extracts of the dried bark were tested. Antimicrobial testing revealed that the ethanol extract demonstrated good antifungal activity against several fungal strains, but the water extract was inactive. The specific fungal strains and quantitative data (e.g., minimum inhibitory concentrations) for A. castaneifolia specifically were not fully detailed in accessible publications. Mild antibacterial inhibition was observed against Staphylococcus epidermis with an inhibition zone of 12 mm at 500 µg/mL (Costa et al., 2008). Overall antifungal evidence is in vitro only and considered preliminary.
Antiviral Activity
Evidence base: in vitro only.
In cell culture testing, the ethyl-acetate extract showed antiviral activity against Sindbis virus at LC50 <1.0 mcg/ml, whereas the water extract was inactive (LC50 >100 mcg/ml). Several kinds of biological activity have been seen in Alchornea species, including activity inhibitory to the replication of HIV-1 and HIV-2. This HIV-inhibitory activity is documented for the genus broadly and for closely related species (particularly A. cordifolia); published peer-reviewed data specifically for A. castaneifolia in this domain are limited to in vitro models, and no clinical significance can be drawn.
Antitumor Activity
Evidence base: preliminary in vitro bioassays only; no clinical data.
In the crown gall tumor inhibition assay, both the ethyl-acetate and water extracts of the dried bark were active at effective concentrations of LC50 = 0.14 mcg/ml and 0.52 mcg/ml, respectively; this assay system is intended to predict antitumor activity. In the anticrustacean assay with Artemia salina, another preliminary test used to predict antitumor activity, the ethanol extract was active at 41 mcg/ml, but the water extract was not active. These are preliminary screening assays, not direct evidence of activity against human cancer. Their results are not predictive of clinical efficacy.
Blood Sugar and Metabolic Effects
Evidence base: traditional use only; no published clinical or preclinical data identified for A. castaneifolia specifically.
Throughout Peru, iporuru is regarded as a remedy for impotency as well as for balancing blood sugar levels in diabetics. This claim rests entirely on ethnobotanical reports. No peer-reviewed pharmacological studies investigating hypoglycemic activity in A. castaneifolia have been identified in available indexed literature. The claim should be regarded as unverified traditional lore.
Aphrodisiac and Reproductive Effects
Evidence base: traditional use and ethnobotanical reports; no controlled clinical trials identified.
Iporuru has a traditional reputation for being a tonic and booster of male libido. The possible pharmacological basis is speculative; the presence of yohimbine in related Alchornea species (and documented in A. castaneifolia by the antiulcer study) is noteworthy, since yohimbine is a known alpha-2-adrenergic receptor antagonist with documented effects on erectile function. However, no studies have quantified yohimbine content in standardized iporuru preparations or demonstrated clinical efficacy for this indication specifically for A. castaneifolia.
Body Systems and Health Areas
Based on available ethnobotanical and pharmacological data, iporuru is associated with the following body systems and health domains:
- Musculoskeletal system: Used as a traditional medicine by the indigenous people of the Amazon as a remedy for rheumatism, arthritis, colds, and muscle pains.
- Gastrointestinal system: Animal studies support gastroprotective and antiulcer activity via multiple mechanisms. Traditional use includes diarrhea prevention and digestive support.
- Immune and antimicrobial: In vitro antifungal, antiviral, and limited antibacterial activity documented for extracts. Reported pharmacological properties include anodyne, antiarthritic, antidiarrhoeal, antifungal, anti-inflammatory, antirheumatic, antitumor, and antiviral activities.
- Reproductive system: Widely used as an aphrodisiac and general tonic to the reproductive system.
- Integumentary (topical): Leaves prepared as paste for topical pain relief and wound care (stingray wounds).
Dosage Forms and Dosages Reported in Research
No standardized human dosage has been established through clinical trials. The following dosages appear solely in the experimental or traditional literature and are reported here as documentation, not as recommendations.
- Animal studies — antiulcer (Hiruma-Lima et al., 2006, J. Ethnopharmacol.): HEL (hydroethanolic leaf extract) at 500 and 1000 mg/kg and HEB (bark) at 1000 mg/kg significantly reduced gastric injuries in mice. The enriched flavonoidic fraction was effective at 100 mg/kg in mice.
- Animal studies — anti-inflammatory (Dunstan et al., 1997, J. Ethnopharmacol.): Stembark (Peru), anti-inflammatory activity with 100% ethanol extract applied externally in male rats at 0.8 mg; stembark prostaglandin synthesis inhibition at 100.0 mcg/ml (COX-1 catalyzed biosynthesis).
- Traditional infusion preparation (ethnobotanical/commercial sources): Traditionally taken in half-cup amounts, 2–3 times daily.
- Traditional bark decoction (Tikuna tribe): One tablespoon of bark decoction taken before meals to prevent diarrhea.
- Traditional tincture: Throughout the Amazon, the bark or leaves are tinctured generally with local rum (aguardiente). No standardized dose has been established.
Safety Considerations
Formal human safety studies on A. castaneifolia are absent from the published peer-reviewed literature. The safety information below is limited to what can be drawn from existing experimental investigations.
Mutagenicity Assessment
A 2010 study published in the Brazilian Journal of Pharmacognosy by Santos et al. investigated the mutagenic potential of A. castaneifolia and the related species A. glandulosa. In view of the popular use of these plants as medicines and the potential risks from their consumption, researchers assessed the mutagenic potential of chloroform and methanol extracts of the leaves, employing the in vivo micronucleus test and the Ames assay. The data obtained showed that the chloroform extracts were not mutagenic. The methanol extract results in the same study context require attention: the methanol extracts of both species of Alchornea were mutagenic in vivo at the largest dose employed. The probable mutagenic agents involved were the aglycone quercetin and amentoflavone, present in both species. This finding is noteworthy: it suggests solvent-dependent mutagenicity at high doses in animal/bacterial models, associated with flavonoid aglycones. However, this in vitro/in vivo preclinical signal does not directly establish mutagenic risk in humans from standard oral preparations.
Oral Safety Data (WebMD/Natural Medicines Database Summary)
When taken by mouth, there is not enough reliable information to know if iporuru is safe or what the side effects might be. When applied to the skin, there is not enough reliable information to know if iporuru is safe or what the side effects might be.
Reported Contraindications and Drug Interactions
The Rain-Tree technical data report lists no known contraindications for the herb. No drug interactions have been formally studied. However, the presence of yohimbine in A. castaneifolia, as documented in the Hiruma-Lima et al. (2006) study, is a pharmacologically relevant concern: yohimbine is an alpha-2-adrenergic receptor antagonist that interacts with antidepressants (especially MAO inhibitors and tricyclics), antihypertensive medications, and stimulants. The extent to which the yohimbine content of standardized iporuru preparations reaches pharmacologically significant concentrations has not been quantified in any published study.
Lack of Human Safety Data
There has been little clinical research on iporuru, despite its long history of use in South American herbal medicine. This absence of clinical data means that toxicological endpoints in humans—including hepatotoxicity, nephrotoxicity, interactions with pharmaceuticals, and safety in pregnancy, lactation, pediatric, and elderly populations—remain entirely unknown from formal evaluation.
Current Research Status and Evidence Limitations
The body of published peer-reviewed research on Alchornea castaneifolia is small. Key points on evidence quality:
- The strongest single study in the literature is the Hiruma-Lima et al. (2006) antiulcer animal study in the Journal of Ethnopharmacology, which used multiple validated rodent ulcer models and included mechanistic investigation.
- The anti-inflammatory finding (Dunstan et al., 1997) is a standard preclinical screen, not a clinical trial.
- The phenolic constituent characterization (Gleńsk et al., 2014, Records of Natural Products) provides the most detailed modern phytochemical profile of the leaf.
- No randomized controlled trials, cohort studies, or any form of prospective human clinical data have been published for any therapeutic indication.
- Most available information derives from ethnobotanical surveys, in vitro assays, and rodent models, which are insufficient to establish efficacy or safety for human use.
- People take iporuru for joint pain, acute pain, diabetes, airway infections, and many other purposes, but there is no good scientific evidence to support any use.
References
Go back